Product Reports Resources Pricing Login Book a demo

PTC Therapeutics

Biotech & Life Sciences · South Plainfield, United States · Founded 1998 · IPO 2013

A science-led, patient-centered biopharmaceutical company focused on discovering, developing and commercializing medicine for patients with rare disease

Valuation $4.14B
Revenue $1.24B
EBITDA $412M

Investors

21 investors on PTC Therapeutics's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series B+ 21 investors entered at this stage
HealthCap
Longwood Fund
HBM BioVentures
Jennison Associates
HBM Healthcare Investments
Novo Holdings
CDIB Capital Group
Rutgers university
Adage Capital
Credit Suisse First Boston
Delphi Ventures
Cercano Management
Manulife Financial
Bay City Capital
Celgene
Credit Suisse
New Medical Technologies
The Column Group
Amgen Ventures
Brookside Capital
CDI Bioscience

Global footprint

Where PTC Therapeutics has talent and traffic

Workforce by country
31 countries with
team presence
🇺🇸 United States69.9%
🇧🇷 Brazil7.6%
🇮🇪 Ireland4.9%
🇨🇭 Switzerland2.6%
🇬🇧 United Kingdom1.7%
Top 5 of 31 shown
Web traffic by country
54K monthly visits
across markets
🇺🇸 United States59.3%
🇬🇧 United Kingdom20.6%
🇨🇦 Canada5%
🇮🇳 India3.7%
🇫🇷 France2.2%
Top 5 markets shown

Talent graph

The shape of PTC Therapeutics's talent

Dealroom maps PTC Therapeutics's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

10 standout operatorsDealroom-flagged across the org
3 AI specialistsincl. 2 core researchers
1,150 employees mappedperson by person
DimensionScore
AI Talentlive Score hidden — book a demo
Engineering Score hidden — book a demo
Product Score hidden — book a demo
Go-to-market Score hidden — book a demo
Leadership Score hidden — book a demo
Research Score hidden — book a demo
Book a demo to unlock PTC Therapeutics's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$168M patent portfolio · 118 active families

Estimated portfolio value
$168M
4.0% of market cap · 127.5× larger than top peer Vividion Therapeutics ($1M)
118 active patent families
Where PTC Therapeutics innovates BiochemistryDiseaseHuntingtons choreaMedicinal chemistryMedicine

Where PTC Therapeutics concentrates vs peers

Each axis is a top-10 topic across PTC Therapeutics and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about PTC Therapeutics

An AI-synthesized read of the highest-engagement posts about PTC Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See PTC Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.